These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25210616)

  • 21. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes.
    Teravskis PJ; Covelo A; Miller EC; Singh B; Martell-Martínez HA; Benneyworth MA; Gallardo C; Oxnard BR; Araque A; Lee MK; Liao D
    J Neurosci; 2018 Nov; 38(45):9754-9767. PubMed ID: 30249789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA damage preceding dopamine neuron degeneration in A53T human α-synuclein transgenic mice.
    Wang D; Yu T; Liu Y; Yan J; Guo Y; Jing Y; Yang X; Song Y; Tian Y
    Biochem Biophys Res Commun; 2016 Dec; 481(1-2):104-110. PubMed ID: 27818201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppression of autophagy in the brain of transgenic mice with overexpression of А53Т-mutant α-synuclein as an early event at synucleinopathy progression.
    Pupyshev AB; Korolenko TA; Akopyan AA; Amstislavskaya TG; Tikhonova MA
    Neurosci Lett; 2018 Apr; 672():140-144. PubMed ID: 29203207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease.
    Sirabella R; Sisalli MJ; Costa G; Omura K; Ianniello G; Pinna A; Morelli M; Di Renzo GM; Annunziato L; Scorziello A
    Cell Death Dis; 2018 Jun; 9(7):725. PubMed ID: 29941946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model.
    Smith WW; Liu Z; Liang Y; Masuda N; Swing DA; Jenkins NA; Copeland NG; Troncoso JC; Pletnikov M; Dawson TM; Martin LJ; Moran TH; Lee MK; Borchelt DR; Ross CA
    Hum Mol Genet; 2010 Jun; 19(11):2087-98. PubMed ID: 20185556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian.
    Mo M; Xiao Y; Huang S; Cen L; Chen X; Zhang L; Luo Q; Li S; Yang X; Lin X; Xu P
    Oncotarget; 2017 Jan; 8(1):15-28. PubMed ID: 27965467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
    Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L
    Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment.
    George S; Mok SS; Nurjono M; Ayton S; Finkelstein DI; Masters CL; Li QX; Culvenor JG
    J Mol Neurosci; 2010 Oct; 42(2):243-54. PubMed ID: 20464527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.
    Kim D; Hwang H; Choi S; Kwon SH; Lee S; Park JH; Kim S; Ko HS
    Acta Neuropathol Commun; 2018 Apr; 6(1):32. PubMed ID: 29703245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alteration of dynein function affects α-synuclein degradation via the autophagosome-lysosome pathway.
    Li D; Shi JJ; Mao CJ; Liu S; Wang JD; Chen J; Wang F; Yang YP; Hu WD; Hu LF; Liu CF
    Int J Mol Sci; 2013 Dec; 14(12):24242-54. PubMed ID: 24351814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease.
    Chu Y; Morfini GA; Langhamer LB; He Y; Brady ST; Kordower JH
    Brain; 2012 Jul; 135(Pt 7):2058-73. PubMed ID: 22719003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blocking meningeal lymphatic drainage aggravates Parkinson's disease-like pathology in mice overexpressing mutated α-synuclein.
    Zou W; Pu T; Feng W; Lu M; Zheng Y; Du R; Xiao M; Hu G
    Transl Neurodegener; 2019; 8():7. PubMed ID: 30867902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
    Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH
    Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice.
    Unger EL; Eve DJ; Perez XA; Reichenbach DK; Xu Y; Lee MK; Andrews AM
    Neurobiol Dis; 2006 Feb; 21(2):431-43. PubMed ID: 16230020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease.
    Koprich JB; Johnston TH; Reyes MG; Sun X; Brotchie JM
    Mol Neurodegener; 2010 Oct; 5():43. PubMed ID: 21029459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unilateral intranigral administration of β-sitosterol β-D-glucoside triggers pathological α-synuclein spreading and bilateral nigrostriatal dopaminergic neurodegeneration in the rat.
    Soto-Rojas LO; Martínez-Dávila IA; Luna-Herrera C; Gutierrez-Castillo ME; Lopez-Salas FE; Gatica-Garcia B; Soto-Rodriguez G; Bringas Tobon ME; Flores G; Padilla-Viveros A; Bañuelos C; Blanco-Alvarez VM; Dávila-Ayala J; Reyes-Corona D; Garcés-Ramírez L; Hidalgo-Alegria O; De La Cruz-López F; Martinez-Fong D
    Acta Neuropathol Commun; 2020 Apr; 8(1):56. PubMed ID: 32321590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood-Derived α-Synuclein Aggregated in the Substantia Nigra of Parabiotic Mice.
    Ma X; Chen L; Song N; Qu L; Wang J; Xie J
    Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
    Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
    Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.